Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, announced today that it will be presenting a poster at the Cancer Immunotherapy: Basic Mechanisms Informing Clinical Applications & Combinations Keystone Symposia taking place March 15-18, 2026, in Québec City, Canada, titled “MST-0312: FAP-targeted LTBR Agonist Induces High Endothelial Venules, Lymphocyte Infiltration and Tertiary Lymphoid Structures in Solid Tumors.” Poster Details: Title: MST-0312: FAP-targeted LTBR Agonist Induces High Endothelial Venules, Lymphocyte Infiltration and Tertiary Lymphoid Structures in Solid Tumors Poster Number: Date: March 16, 2026 Time: 1:00-3:00 p.m. ET Session Title: Poster Session 1 About MST-0312 MST-0312 is a first-in-class targeted lymphotoxin beta receptor (LTBR) agonist bispecific antibody designed to induce tertiary lymphoid structures (TLS) and high endothelial venules (HEV) in solid tumors. A remarkable body of clini
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Keytruda's reign continues; pharma's megadeal drought [Yahoo! Finance]Yahoo! Finance
- ????????????????: 2036????????? [CNET News]CNET News
- Merck's WELIREG Kidney Cancer Trials Deepen Oncology Growth Story [Yahoo! Finance]Yahoo! Finance
- Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150 [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (MRK) had its price target raised by Wells Fargo & Company from $135.00 to $150.00. They now have an "overweight" rating on the stock.MarketBeat
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 3/12/26 - Form 3
- 2/24/26 - Form 10-K
- 2/17/26 - Form 13F-HR
- MRK's page on the SEC website